Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 23, 2015

Primary Completion Date

June 15, 2020

Study Completion Date

June 15, 2020

Conditions
Anxiety DisorderDepressionRecurrent Breast CancerStage IA Breast CancerStage IB Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer
Interventions
DRUG

minocycline hydrochloride

100 mg bid given by mouth for 9 weeks

OTHER

placebo

Placebo given by mouth for 9 weeks

OTHER

laboratory biomarker analysis

Correlative blood levels for cortisol, high sensitivity c-reactive protein (hs-CRP) and inflammatory factors including but not limited to IL-6, TNF-α, IL-1β, and MCP-1 will also be obtained weekly on protocol.

OTHER

Questionnaire administration

The CES-D and STAI will be administrated weekly.

Trial Locations (1)

43210

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT02203552 - Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer | Biotech Hunter | Biotech Hunter